Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S424/00—Drug, bio-affecting and body treating compositions
  • Y10S424/05—Stick

Definitions

• the present invention relates to certain novel and unobvious formulations of certain known antimycotic azole derivatives, which exhibit a higher release of active compounds and accordingly make short-duration therapy possible.
• Formulations of antimycotic derivatives for the treatment of mycoses in warm-blooded animals, especially mycoses of the skin and of the skin appendages, have already been disclosed. With these formulations, the duration of therapy required for complete cure was 14 to 21 days.
• a stick formulation of an antimycotic agent with higher release of the antimycotic active compound(s), containing one or more antimycotic azole derivatives, 3 to 5% by weight, relative to the formulation, of benzyl alcohol, 2.5 to 10% by weight, relative to the formulation, a spreading agent, and one or more stick formulation auxiliaries.
• the stick formulations of the present invention release the active compound to a greater degree than the mentioned prior formulations and as a result permit shortening the duration of therapy to 1 day. This effect of higher release of active compound can be as much as a power of ten.
• Active compounds which can be formulated in this manner are any of the antimycotically active derivatives, especially antimycotically active imidazole derivatives and triazole derivatives. They are present in the agents according to the invention in amounts of 0.05 to 1% by weight, preferably of 0.1 to 1% by weight, relative to the weight of the formulation.
• spreading agents there are understood oily liquids which spread particularly well on the skin, [R. Keymer, Pharm. Ind. 32 1970, 577-581].
• Particularly suitable spreading agents for use in the in the formulations according to the invention are the following compounds:
• Silicone oils of various viscosities are silicone oils of various viscosities.
• Fatty acid esters such as ethyl stearate, di-n-butyl adipate, hexyl laurate, dipropylene glycol pelargonate, esters of a branched fatty acid of medium chain length with saturated C 16 -C 18 fatty alcohols, isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of saturated fatty alcohols of chain length C 12 -C 18 , isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy fatty acid esters such as synthetic duck preen gland fat, dibutyl phthalate, diisopropyl adipate, ester mixtures related to the latter, myristyl lactate, cetyl lactate, 2-ethylhexyl palmitate and myristyl myristate.
• Triglycerides such as caprylic/capric acid triglyceride, triglyceride mixtures with vegetable fatty acids of chain length C 8 -C 12 or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids, which optionally also contain hydroxyl groups and monoglycerides of C 8 /C 10 -fatty acids.
• Fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetyl/stearyl alcohol and oleyl alcohol.
• Fatty acids such as, for example, oleic acid.
• Particularly suitable spreading oils are the following: isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of saturated fatty alcohols of chain length C 12 -C 18 , waxy fatty acid esters such as synthetic duck preen gland fat, silicone oils, and an isopropyl myristate/isopropyl stearate/isopropyl palmitate mixture.
• auxiliaries and/or basic formulation auxiliaries can be used in the preparation of the agents according to the invention:
• non-ionic emulsifiers prepared by reacting higher saturated fatty alcohols with ethylene oxide.
• Glycerol high viscosity paraffin, low viscosity paraffin, triethanolamine, collagen, allantoin, novantisolic acid, perfume oils, sodium hydroxide, propylene glycol, dipropylene glycol and tripropylene glycol and waxes.
• Substances which, for example, can stabilise a suspension, for example colloidal silica and montmorillonite.
• surfactants this includes emulsifiers and wetting agents, for example
• anionic surfactants such as Na laurylsulphate, fatty alcohol-ether-sulphates, monoalkyl-/dialkyl-polyglycol-ether orthophosphoric acid ester monoethanolamine salt;
• cationic surfactants such as cetyltrimethylammonium chloride
• ampholytic surfactants such as di-Na-N-lauryl- ⁇ -iminodipropionate or lecithin;
• non-ionic surfactants for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, cetyl alcohol and glycerol monostearate, polyoxyethylene stearate and alkylphenol polyglycol ethers.
• Stabilisers for preventing the chemical degradation which occurs with some active compounds, such as antioxidants, for example tocopherols and butylhydroxyanisole.
• Suitable gel-forming agents are macromolecular compounds which can dissolve or swell both in water and in organic solvents and which, after drying, form a type of film.
• ionic macromolecules in their salt form, which are employed. They include, inter alia, sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin-semiglycolate, alginic acid and propylene glycol alginate as the sodium salt, gum arabic, xanthan gum and guar gum.
• Amphoteric macromolecules such as protein derivatives, for example gelatins, are just as suitable as non-ionic polymers, for example methylcellulose, hydroxypropylcellulose and soluble starches, which conform to the above requirements.
• Suitable solvents are water as well as any of the water-miscible solvents. It is possible to use, for example, alkanols, such as ethanol and isopropyl alcohol, propylene glycol, methyl CELLOSOLVE (ethylene glycol monomethyl ether), CELLOSOLVE (ethylene glocyl monoethyl ether) esters, morpholines, dioxane, dimethylsulphoxide, dimethylformamide, tetrahydrofuran and cyclohexanone.
• alkanols such as ethanol and isopropyl alcohol
• propylene glycol propylene glycol
• methyl CELLOSOLVE ethylene glycol monomethyl ether
• CELLOSOLVE ethylene glocyl monoethyl ether
• One or more solvents can be employed in the preparation of the formulations according to the invention.
• the individual components were fused or dissolved at 70° C. to 75° C.
• the finished mix was deaerated by leaving the mass, in the dissolved state, to stand for quarter of an hour. Heating the melt for too long, and to a higher temperature than necessary, was to be avoided.
• the sticks were cast at about 70° C. No air was allowed to be trapped thereby. A glossy surface was achieved by passing a flame over the sticks.
• Trichophyton-infected Pirbright white guineapigs having an average weight of 600 g were used.
• the backs of the animals were shorn with an electric hair-cutter, so that about 1/10 mm long hair stumps were left.
• the infection with Trichophyton mentagrophytes was effected by lightly rubbing a spore suspension of the causative organism, germinated in Sabouraud nutrient solution for 24 hours, over an area of size about 2 ⁇ 2 cm of the shorn backs of the animals. Per animal, 0.5 ml of germ suspension, containing 1-3 ⁇ 10 5 infectious fungal particles, was applied.
• the first symptoms of the dermatophytosis manifested themselves 2-3 days after infection as redness and scurfing of the skin.
• the dermatophytosis was most pronounced about 14 days after infection: loss of hair over entire areas, and bleeding integument defects within an inflammatorily modified, scurfy edge zone.
• formulations which contain no benzyl alcohol and no spreading agent were used, as effect corresponding to that of the formulations according to the invention could only be achieved after three applications.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Organic Chemistry (AREA)
• Dermatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cephalosporin Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6125514

Family Applications (1)

Country Status (14)

Cited By (12)

Families Citing this family (8)

Citations (7)

Family Cites Families (3)

• 1981
  • 1981-02-23 DE DE19813106635 patent/DE3106635A1/de not_active Withdrawn
• 1982
  • 1982-02-03 NO NO820319A patent/NO820319L/no unknown
  • 1982-02-05 US US06/346,479 patent/US4457938A/en not_active Expired - Fee Related
  • 1982-02-10 AU AU80326/82A patent/AU8032682A/en not_active Abandoned
  • 1982-02-11 AT AT82101001T patent/ATE6988T1/de not_active IP Right Cessation
  • 1982-02-11 DE DE8282101001T patent/DE3260099D1/de not_active Expired
  • 1982-02-11 EP EP82101001A patent/EP0058887B1/de not_active Expired
  • 1982-02-19 FI FI820563A patent/FI820563L/fi not_active Application Discontinuation
  • 1982-02-19 IL IL65057A patent/IL65057A/xx unknown
  • 1982-02-22 PH PH26895A patent/PH18258A/en unknown
  • 1982-02-22 CA CA000396788A patent/CA1169770A/en not_active Expired
  • 1982-02-22 ZA ZA821137A patent/ZA821137B/xx unknown
  • 1982-02-22 DK DK76582A patent/DK76582A/da not_active Application Discontinuation
  • 1982-02-22 JP JP57026173A patent/JPS57156413A/ja active Pending
  • 1982-02-22 ES ES509798A patent/ES509798A0/es active Granted

Patent Citations (7)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events